Signature by Lagardère of a €1.25 Billion Multicurrency Syndicated Credit Facility with a Maturity of 5 Years

PARIS--(BUSINESS WIRE)--

Regulatory News:

Lagardère SCA (Paris: MMB) announces the signature of a €1.25 billion multicurrency syndicated credit facility for general corporate purposes. This facility replaces the previous €1.645 billion facility, signed in 2011.

The new facility has a 5 year maturity (with two one-year extension options). This achievement highlights the confidence our bank partners have on the financial profile and the prospects of the Group.

The syndication includes 15 banks:

• 5 Bookrunners: BNP Paribas, Crédit Agricole CIB, HSBC France, Natixis, Société Générale CIB ;
• 3 Mandated Lead Arrangers: Commerzbank, ING, JP Morgan;
• 7 Arrangers: Banco Santander, Barclays, Crédit Agricole d’Ile de France, Citibank, Crédit Lyonnais, Mizuho, Unicredit.

This new syndicated credit facility allows the Group to bolster its liquidity profile while decreasing the average cost of debt.

The Lagardère group is a global leader in content production and distribution whose powerful brands leverage its virtual and physical networks to attract and enjoy qualified audiences.It is structured around four business lines: Books and e-Books; Travel Retail and Distribution; Press, Audiovisual, Digital and Advertising Sales Brokerage; Sports and Entertainment.Lagardère shares are listed on Euronext Paris.www.lagardere.com

Lagardère SCA
Press Contacts
Thierry FUNCK-BRENTANO, tel. +33 1 40 69 16 34
[email protected]
or
Ramzi KHIROUN, tel. +33 1 40 69 16 33
[email protected]
or
Investor Relations Contact
Anthony MELLOR, tel. +33 1 40 69 18 02
[email protected]

Source: Lagardère SCA

You May Also Be Interested In

• IMC to Produce Comprehensive, Practical Guidelines for IoT Security
• Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
• Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)